Officials said the purchase agreement with CSL Seqirus is part of longer-term plans to shore up vaccine supply against a wider range of pathogens that have pandemic potential.
Though the funding covers melioidosis and Marburg tests, ASPR said the new capability can be repurposed to develop and produce tests for other biological threats when needed.